Last checked at 28 Jun 2013 07:00
Proteome Sciences plc
Patent Statement
28 June 2013
The Company has again been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in the light of recent US court rulings on patent eligibility, in particular the court's recent ruling against Myriad that patents will not be allowed on genes. This has no bearing on Proteome Sciences' intellectual property. Shareholders will be pleased to know that the Company received subsequent notification this week from the US Patent and Trademark Office of the allowance of a new patent in Huntington's disease. The Directors conclude that these decisions do not change the status of the Company's issued and pending US applications or impact its granted US patents which continue to remain in good standing.
Ends
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Chief Executive Officer | Tel: +44 (0)1932 865065 |
Dr. Ian Pike, Chief Operating Officer James Malthouse, Finance Director | |
Nominated Adviser | |
Cenkos Securities plc | |
Stephen Keys/Camilla Hume | Tel: +44 (0)20 7397 8900 |
Public Relations | |
FTI Consulting | IKON Associates |
Ben Atwell / Simon Conway / Mo Noonan | Adrian Shaw |
Tel: +44 (0)20 7269 7116 | Tel: +44 (0)1483 271291 |
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker
assays to pharmaceutical, biotechnology and diagnostics companies.
Visit: http://www.proteomics.com